Sort

Search

01/08/2024 PHASE 2 TRIAL OF RILIPRUBART IN CIDP: EFFECT ON COMPLEMENT BIOMARKERS AND NEUROFILAMENT LIGHT CHAIN
Querol, L, Lewis, RA, Van Doorn, PA, Hughes, RAC, Storek, M, Rajagopal, V, Chow, T, Luo, XD, Alonso-Alonso, M, Atassi, N, Hartung, HP. PHASE 2 TRIAL OF RILIPRUBART IN CIDP: EFFECT ON COMPLEMENT BIOMARKERS AND NEUROFILAMENT LIGHT CHAIN. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2024 CLINICAL AND GENETIC SPECTRUM OF PATIENTS WITH BAG3-RELATED NEUROMUSCULAR DISORDERS IN EUROPE
Fernandez-Eulate, G, Gitiaux, C, Thiele, S, Jungbluth, H, Audic, F, Potulska-Chromik, A, Marini-Bettolo, C, Davion, JB, de la Tassa, GM, Olivé, M, de la Hoz, CPDF, Isapof, A, Töpf, A, Walter, M, Angelini, C, Claeys, K, Kostera-Pruszczyk, A, Attarian, S, Straub, V, Domínguez-González, C, Vissing, J, Metay, C, Khraiche, D, Wahbi, K, Stojkovic, T. CLINICAL AND GENETIC SPECTRUM OF PATIENTS WITH BAG3-RELATED NEUROMUSCULAR DISORDERS IN EUROPE. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2024 EFFICACY AND SAFETY OF SUBCUTANEOUS (SC) EFGARTIGIMOD PH20 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: ADHERE/ADHERE plus TRIALS
Allen, J, Van Doorn, PA, Basta, I, Dysgaard, T, Eggers, C, Guptill, J, Gwathmey, K, Hewamadduma, C, Hofman, E, Hussain, Y, Kuwabara, S, Le Masson, G, Leypoldt, F, Lin, J, Lipowska, M, Lowe, M, Pinter, GL, Querol, L, Simu, MA, Chang, T, Tse, A, Ulrichts, P, Van Hoorick, B, Yamasaki, R, Lewis, RA. EFFICACY AND SAFETY OF SUBCUTANEOUS (SC) EFGARTIGIMOD PH20 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: ADHERE/ADHERE plus TRIALS. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2024 Assessing predictors of adequate individual buprenorphine maintenance dosage for the treatment of opioid use disorder: Listening to the patient
González-Saiz, F, Vergara-Moragues, E, Trujols, J, Alcaraz, S, de los Cobos, JP. Assessing predictors of adequate individual buprenorphine maintenance dosage for the treatment of opioid use disorder: Listening to the patient. INTERNATIONAL JOURNAL OF DRUG POLICY. 2024; 130DOI:10.1016/j.drugpo.2024.104519. PMID:39024687. IF:4.400(Q1/1D).